Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …

Antibodies are highly potent therapeutic scaffolds with more than a hundred different
products approved on the market. Successful development of antibody-based drugs …

Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …

There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

Therapeutic monoclonal antibodies and their derivatives are key components of clinical
pipelines in the global biopharmaceutical industry. The availability of large datasets of …

Feeding biopharma pipelines with biotherapeutic candidates that possess desirable
developability profiles can help improve the productivity of biologic drug discovery and …

Effective translation of breakthrough discoveries into innovative products in the clinic
requires proactive mitigation or elimination of several drug development challenges. These …

Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …

Deep learning, aided by the availability of big data sets, has led to substantial advances
across many disciplines. However, many scientific problems of practical interest lack …